HIF-1α (Hypoxia-Inducible Factor 1-alpha) is the oxygen-sensitive subunit of the HIF-1 transcription factor heterodimer. It is the master regulator of cellular adaptation to low oxygen tension (hypoxia), controlling the expression of hundreds of genes involved in energy metabolism, angiogenesis, erythropoiesis, and cell survival . HIF-1α dimerizes with HIF-1β (ARNT) to form the active transcription factor, which binds to hypoxia-response elements (HREs) in the promoters of target genes. Under normoxic conditions, HIF-1α is continuously degraded via the VHL-dependent ubiquitin-proteasome pathway. Under hypoxia, degradation is inhibited, allowing HIF-1α to accumulate, translocate to the nucleus, and activate its transcriptional program .
| HIF-1α Protein |
|---|
| Protein Name | Hypoxia-Inducible Factor 1-Alpha |
| Gene | [HIF1A](/genes/hif1a) |
| UniProt ID | [Q16665](https://www.uniprot.org/uniprot/Q16665) |
| PDB IDs | 1H2M, 4H6J |
| Molecular Weight | 92.6 kDa |
| Subcellular Localization | Nucleus, Cytoplasm |
| Protein Family | bHLH-PAS transcription factor family |
HIF-1α is a 826-amino acid protein with distinct structural domains:
- bHLH domain (residues 1-70): Basic helix-loop-helix region required for DNA binding to the core sequence 5'-RCGTG-3' (HRE)
- PAS-A domain (residues 80-160): Per-Arnt-Sim homology domain A — involved in heterodimerization
- PAS-B domain (residues 230-330): Per-Arnt-Sim homology domain B — also contributes to dimerization
- ODD domain (residues 400-600): Oxygen-dependent degradation domain — contains hydroxylation sites (Pro402, Pro564) regulated by PHD enzymes
- N-TAD (residues 500-570): N-terminal transactivation domain — interacts with p300/CBP coactivators
- C-TAD (residues 780-826): C-terminal transactivation domain — primary site of p300 recruitment
Heterodimerization with HIF-1β (ARNT) occurs via the PAS domains, creating a functional transcription factor complex that recruits the coactivator p300/CBP via the TAD domains.
The canonical regulation of HIF-1α is oxygen-dependent:
- Normoxia: Under well-oxygenated conditions, prolyl hydroxylases (PHD1/EGLN2, PHD2/EGLN1, PHD3/EGLN3) hydroxylate specific proline residues (Pro402, Pro564) in the ODD domain
- VHL recognition: Hydroxylated HIF-1α is recognized by the von Hippel-Lindau (VHL) tumor suppressor protein, which is part of an E3 ubiquitin ligase complex
- Ubiquitination and degradation: polyubiquitination targets HIF-1α for proteasomal degradation, maintaining very low baseline levels
- Hypoxia: Low O₂ inhibits PHD activity (PHDs require O₂ as a cosubstrate), preventing hydroxylation and VHL recognition. Unhydroxylated HIF-1α accumulates, translocates to the nucleus, and drives transcription
- Asparagine hydroxylation: Factor inhibiting HIF (FIH) hydroxylates Asn803 in the C-TAD under moderate hypoxia, blocking p300 recruitment
- Post-translational modifications: Phosphorylation (by GSK3β, MAPK), acetylation (by p300), and SUMOylation modulate stability and activity
- Transcriptional and translational control: HIF1A mRNA can be translationally upregulated under stress conditions
- Feedback regulation: HIF-1 induces PHD2 and PHD3 expression, creating a negative feedback loop that tunes the hypoxic response
HIF-1α is the central mediator of the cellular adaptive response to hypoxia:
- Glycolysis upregulation: Induces GLUT1 (SLC2A1), hexokinases (HK1, HK2), phosphofructokinase (PFKL), and pyruvate dehydrogenase kinase 1 (PDK1), shifting energy production from oxidative phosphorylation to glycolysis
- Angiogenesis: Induces VEGF (VEGFA) and VEGFR2 expression to promote new blood vessel formation
- Erythropoiesis: Induces EPO (erythropoietin) to stimulate red blood cell production
- Autophagy: Activates BNIP3 and other autophagy genes to promote cell survival under stress
- Anti-apoptotic genes: Induces BCL2, survivin (BIRC5), and erythropoietin for direct neuroprotective effects
- DNA repair genes: Upregulates genes involved in base excision repair and homologous recombination
- Stress response genes: Activates HO-1 (heme oxygenase 1) and other antioxidant response genes
- Brain: Regulates cerebral blood flow, metabolic adaptation to ischemia, and neuroprotection
- Retina: Critical for retinal vascularization and photoreceptor survival
- Kidney: Central regulator of erythropoietin production
- Heart: Cardioprotection during ischemic episodes
The role of HIF-1α in neurodegenerative diseases is complex and context-dependent, with both neuroprotective and detrimental effects documented .
In AD, HIF-1α plays a dual role:
Neuroprotective effects:
- HIF-1α activation is a compensatory response to chronic cerebral hypoperfusion observed in AD
- VEGF induction promotes angiogenesis and may improve cerebral blood flow
- Glycolytic shift helps neurons maintain ATP production despite mitochondrial dysfunction
- Induction of amyloid-degrading enzymes (IDE, MMP9) may reduce Aβ burden
- EPO and other HIF target genes provide direct neuroprotection
Detrimental effects:
- Chronic HIF-1α activation may promote Aβ production via increased APP expression
- Can contribute to neuroinflammation through VEGF-mediated blood-brain barrier disruption
- May promote tau hyperphosphorylation through metabolic stress pathways
Postmortem AD brain studies show increased HIF-1α expression, particularly in neurons surrounding amyloid plaques, suggesting a sustained but insufficient adaptive response .
In PD, HIF-1α provides neuroprotection to dopaminergic neurons :
- Ischemic preconditioning: Prior exposure to mild hypoxia via HIF-1α activation protects neurons against subsequent severe insults
- Mitochondrial protection: HIF-1α helps neurons cope with mitochondrial Complex I deficiency common in PD
- α-synuclein toxicity: HIF-1α activation can reduce α-synuclein aggregation and protect against dopaminergic neuronal death
- Inflammatory modulation: Regulates microglial activation and neuroinflammatory responses
¶ Stroke and Ischemia
HIF-1α is acutely protective in cerebral ischemia:
- Ischemic preconditioning (IPC) induces HIF-1α and protects against subsequent stroke
- HIF-1α target genes (EPO, VEGF, GLUT1, BDNF) promote neuronal survival and tissue perfusion
- Pharmacologic HIF activation before stroke is neuroprotective in animal models
- However, timing is critical — excessive late-phase HIF activation may worsen outcomes
¶ ALS and Motor Neuron Disease
- HIF-1α dysregulation is observed in SOD1 mouse models and human ALS tissue
- Motor neurons are particularly vulnerable to hypoxic stress
- Therapeutic targeting of HIF pathways is under investigation
HIF-1α plays context-dependent roles in MS:
- Myelin repair: HIF-1α promotes oligodendrocyte precursor differentiation
- Blood-brain barrier: HIF-1α regulates BBB integrity
- Autoimmunity: T cell HIF-1α affects cytokine production
Cerebral small vessel disease shares features with AD:
- Chronic hypoperfusion: Reduced cerebral blood flow in VCID
- White matter lesions: HIF-1α in demyelinating lesions
- Therapeutic potential: HIF stabilization may improve outcomes
HIF-1α responds to acute brain injury:
- Acute neuroprotection: Early HIF-1α activation is protective
- Angiogenesis: Promotes revascularization
- Long-term outcomes: Complex, timing-dependent effects
¶ COVID-19 and the Brain
Emerging evidence links COVID-19 to neurological symptoms:
- Hypoxia: Severe COVID-19 causes cerebral hypoxia
- Cognitive impairment: "Long COVID" includes brain fog
- HIF-1α: May mediate both protective and pathological responses
HIF-1α regulates hundreds of genes through hypoxia response elements (HREs, 5'-RCGTG-3'):
| Gene |
Function |
Relevance to Neurodegeneration |
| GLUT1 (SLC2A1) |
Glucose transporter |
Metabolic adaptation |
| HK1/HK2 |
Hexokinases |
Glycolysis |
| PDK1 |
Pyruvate dehydrogenase kinase |
Metabolic shift |
| LDHA |
Lactate dehydrogenase |
Glycolysis |
| Gene |
Function |
Relevance to Neurodegeneration |
| VEGFA |
Vascular endothelial growth factor |
Angiogenesis, also neurotoxic in excess |
| ANGPTL4 |
Angiopoietin-like 4 |
Permeability |
| PLIN2 |
Perilipin 2 |
Lipid metabolism |
| Gene |
Function |
Relevance to Neurodegeneration |
| EPO |
Erythropoietin |
Neuroprotection |
| BCL2 |
Anti-apoptotic |
Cell survival |
| survivin (BIRC5) |
Inhibitor of apoptosis |
Cell division |
| NQO1 |
NADPH quinone dehydrogenase |
Antioxidant |
| Gene |
Function |
Relevance to Neurodegeneration |
| BNIP3 |
Pro-autophagic |
Mitophagy |
| BNIP3L/NIX |
Pro-autophagic |
Mitophagy |
| MAP1LC3B |
Microtubule-associated |
Autophagosome |
| p62/SQSTM1 |
Selective autophagy |
Protein clearance |
HIF-1α can be activated without hypoxia:
- PI3K/AKT/mTOR pathway: AKT promotes HIF-1α translation
- MAPK pathway: ERK1/2 enhances HIF-1α transcriptional activity
- GSK3β: Paradoxically promotes degradation
- NF-κB: Cross-talk with HIF-1α transcription
- TNF-α: Can stabilize HIF-1α
- IL-1β: Synergistic activation
- Succinate accumulation: Inhibits PHD, stabilizes HIF
- Fumarate: Fumarate accumulation (FH mutations) stabilizes HIF
- Reactive oxygen species: Can promote HIF activation
| Feature |
HIF-1α |
HIF-2α (EPAS1) |
| Gene |
HIF1A |
EPAS1 |
| Expression |
Ubiquitous |
Endothelial cells, brain |
| Target genes |
Overlapping but distinct |
Some unique targets |
| Role in cancer |
Promotes proliferation |
Promotes tumor growth |
| Neuronal role |
Acute response |
Chronic hypoxia |
- Constitutively expressed
- Shared subunit for HIF-1α and HIF-2α
- Essential for dimerization
- Not oxygen-regulated
These small molecules stabilize HIF-1α by inhibiting PHD enzymes, mimicking the hypoxic response:
| Drug |
Target |
Status |
Notes |
| Roxadustat (FG-4592) |
PHD1/2/3 |
Approved (ESA) |
FDA-approved for anemia; CNS penetration being studied |
| Vadadustat (AKB-6548) |
PHD1/2/3 |
Approved (ESA) |
Similar profile to roxadustat |
| Daprodustat (GSK1278863) |
PHD1/2/3 |
Approved (ESA) |
Approved for anemia in CKD |
| FG-2216 |
PHD |
Preclinical |
First-generation compound |
Neurodegeneration research:
- Roxadustat and vadadustat show neuroprotective effects in mouse models of stroke, AD, and PD
- Preconditioning effect: PHD inhibitors administered 24-48h before stroke reduce infarct volume
- Clinical trials for neuroprotection are in early stages [@vangeel2020; @masson2019]
- Viral delivery of HIF-1α or PHD shRNA to the brain
- Exosomes loaded with HIF-1α mRNA for targeted delivery
- Cell-permeable peptides stabilizing HIF-1α
- DMOG (dimethyloxalylglycine): Pan-PHD inhibitor, widely used in research, not clinically available
- CoCl₂: Chemical hypoxia mimetic, induces HIF-1α but toxic at high doses
- Angiotensin II: Indirectly activates HIF-1α via AT1 receptor
| Partner |
Interaction Type |
Functional Consequence |
| HIF-1β (ARNT) |
Heterodimerization |
Forms active transcription factor complex |
| VHL |
E3 ligase binding |
Normoxic degradation via ubiquitin-proteasome |
| PHD1/2/3 (EGLN1/2/3) |
Prolyl hydroxylation |
Oxygen-dependent regulation |
| FIH (HIF1AN) |
Asparaginyl hydroxylation |
Blocks p300 recruitment |
| p300/CBP |
Coactivator recruitment |
Transcriptional activation |
| HDAC1/2/3 |
Deacetylase interaction |
Modulates transcriptional activity |
| GSK3β |
Phosphorylation |
Promotes proteasomal degradation |
| PIN1 |
Prolyl isomerization |
Modulates stability and activity |
- Temporal dynamics: Understanding when HIF-1α is protective vs. harmful in each disease stage
- Cell type specificity: Neuronal vs. glial HIF-1α may have opposing effects
- Combination therapy: HIF-PHI + conventional neuroprotective agents
- Biomarker development: Imaging HIF-1α activation as a predictive biomarker
- Novel PHD inhibitors: Next-generation compounds with improved CNS penetration